Compound Screening TRIZ Cases

Loop insertions in variant Fc-polypeptides increase neonatal Fc receptor binding at acidic pH, extending in vivo half-lives and reducing dosing frequency.

Single-molecule imaging quantifies GPCR diffusive dynamics on cell membranes to evaluate receptor activity.

Screening candidate substances by measuring Zip11 activity and expression levels to identify agents capable of modulating biological aging processes.

Resin beads with cleavable linkers attach living cells to test compounds for rapid physiological effect detection.

Glycoenzyme inhibitors target alpha-4GalT to modulate SSEA-3 synthesis, resolving poor marker selectivity for cancer stem cell enrichment.

Cannabinoids activate TRPV2 channels to enable selective ion flow measurement, resolving the lack of specific agonists in high-temperature screening systems.

Denaturing wash removes endotoxins from phagocytable particles, preventing background activation that masks low-level antigen-specific T-cell responses.

Site-directed mutations in the MGLL cap-domain eliminate detergent requirements during purification, enabling atomic-resolution X-ray diffraction.

A pseudoviral assay system measures infectivity levels using target cells expressing ACE-2 and nAChR receptors.

Detecting AGPAT9 and ANXA10 mRNA levels in EGF-cultured adipose stem cells provides objective quality control for therapeutic agents.

Amphiphilic molecules modulate biomolecular condensates to restore transcriptional activity, addressing functional interference from repeat expansion mutations.

Inhibiting complement activation prevents pathological synapse loss, maintaining neuronal connectivity to address early Alzheimer's disease damage.

CRISPR/Cas9 modifies Cdc20 translation start sites to enhance wild-type expression, preventing mitotic slippage and improving treatment efficacy.

Antibodies detect keratin degradation peptides for rapid periodontal disease diagnosis.

A tryptophanyl-tRNA synthetase inhibitor blocks myeloid-derived suppressor cell differentiation to enhance anticancer efficacy.

Specific probe compounds bind to Bruton's tyrosine kinase to quantify inhibitor occupancy in biological samples.

Segmenting signaling pathways using specific receptor profiles and ligand combinations reduces unwanted side effects from redundant interactions.

Flunarizine directs mitochondria into lysosomes for independent removal, avoiding nuclear instability caused by gene overexpression methods.

Dichlorofluorescein detects OATP1B1 transport activity via measurable fluorescence intensity changes.

Dynamic fluid flow mimics in vivo conditions, enabling accurate drug testing at physiologic concentrations.

Quantitative protein interaction analysis resolves genomic profiling gaps by measuring signal intensity to predict drug responsiveness.

Segmented biosensors enable high-resolution 3D imaging of cellular responses, overcoming limited resolution in traditional models.

Screen drug candidates by measuring calcium and phosphatidylinositol phosphate interaction using isothermal titration calorimetry.

A peptide composition inhibits OCT4 function to suppress cancer stem cell proliferation.

A scaffold-free three-dimensional pulmonary model tissue culture uses specific cell ratios and Wnt11 treatment to enhance ATII type differentiation.

Cells expressing sialoadhesin and CD163 enable Porcine Reproductive and Respiratory Syndrome Virus replication without antigenic changes.

Screening small molecules to inhibit MASP protein activity using mannose-binding lectin and calcium binding assays.

NMR system acquires data at multiple echo times to create a chemical shift domain for identifying metabolites by two chemical shifts.

Tandem mass spectrometry monitors unique peptide transitions to quantify CYP1A2, bypassing unreliable mRNA-based induction prediction methods.

Segmenting diagnosis with a multi-functional biomarker panel resolves the contradiction between diagnostic accuracy and differential capability for Alzheimer's.

Segmented H3.3 peptides induce cytotoxic T lymphocyte responses against glioma cells, overcoming immune tolerance to the K27M mutation.

Anti-hamster phospholipase B-like 2 antibodies enable specific detection and quantification of host cell proteins in recombinant polypeptide preparations.

A differentiation medium containing EGFR, Notch, and Wnt inhibitors drives progenitor cells into enteroendocrine cell populations.

A cellular assay measures ERG protein levels as a proxy for BAF complex interaction strength to identify candidate compounds.

Segmenting xenobiotic measurements resolves diagnostic ambiguity by isolating specific metabolic profiles from other neurodegenerative diseases.

Fluorescent peptide domains linked to ATF6 enable real-time pathway activation detection, resolving the bottleneck of insensitive ER stress assessment.

InPAkt eliminates cell movement artifacts by combining Akt PH domains with FRET pairs, enabling precise subcellular monitoring of phosphoinositide dynamics.

Coupling a B cell variable immunoglobulin region to an identification region enables affinity-matured human antibody production without extensive screening.

Specific thresholds for isomerization, deamidation, oxidation, and glycosylation preserve tezepelumab potency during manufacturing and storage.

Targeted antibodies bind the PAR1 cleavage site between Arg41 and Ser42, blocking MMP1 access to resolve metastasis inhibition challenges.

Fc-tagged S1RBD mediates picogram-level detection, resolving sensitivity and reagent quantity constraints.

Universal CD3 binding domains enable cross-species therapeutic use, reducing reliance on chimpanzee testing while maintaining safety validation.

siRNA inhibitors block USP1 deubiquitinase to accumulate PCNA-Ub and FANCD2-Ub, enhancing translesion synthesis against radiation damage.

Targeting MK2/3 signaling reduces hepatic glucose production, addressing obesity-induced insulin resistance and metabolic syndrome limitations.

Modifying the CH3 domain promotes correct heavy chain pairing while maintaining binding affinity despite APRIL and BAFF interference.

Targeted peptide sequences inhibit aberrant G-alpha-q signaling, reducing tumor progression and metastasis in uveal melanoma.